[ad_1]
Hayward, Calif.–(ANTARA/Enterprise Wire)– Mawi DNA Applied sciences (Mawi), a frontrunner in biosample assortment applied sciences, proclaims the corporate acquired CE Mark and UK MHRA approval for its portfolio of iSWAB non-invasive assortment units. This approval consists of Mawi’s HemaSure-OMICS complete blood assortment tubes for gDNA, cfDNA, and RNA from the identical pattern and the NextSWAB 100% injection molded swab.
The CE Certification, internationally acknowledged, signifies that Mawi’s merchandise conform to European and UK medical machine directives. With CE Mark and UK MHRA approval, Mawi is ready to commercialize its full vary of merchandise within the UK, European Union and all international locations recognizing this molecular diagnostic assays commonplace.
“CE Mark and UK MHRA approvals are important milestones for Mawi,” stated Dr. Bassam El-Fahmawi, CEO of Mawi DNA Applied sciences. “It permits us to develop the utility and entry of our revolutionary biosample assortment applied sciences from analysis use solely to the in vitro molecular diagnostics market in Europe. “Additional, it opens alternatives to collaborate and accomplice with European firms and organizations to combine our merchandise into regulated, high-value market segments corresponding to molecular diagnostic testing, medical trials, and infectious illness surveillance.”
“Receiving the CE Mark and UK MHRA is a superb accomplishment for our firm,” Hanzel Lawas, QMS and Operations Supervisor at Mawi, stated. “Along with our current ISO 9001/13485 certification, it reaffirms our conformity with the IVD Medical Machine directives and our dedication to ship prime quality merchandise that meet our buyer’s expectations and regulatory necessities.”
About Mawi DNA Applied sciences
Contacts
Traders:
Jerome David, VP of Gross sales and Advertising and marketing
Media Contact:
Susan Tellem, APR, RN, BSN
Supply: Mawi DNA Applied sciences
[ad_2]
Source link